Similar Papers

Paper Title
Journal
Date
Author
Sequential Azacitidine and High-Dose Lenalidomide for Relapsed and Refractory High-Risk MDS and AML: Interim Analysis of a Phase 2 Study
Daniel A Pollyea ... Jonathan A Gutman
Blood | VOL. 124
Daniel A Pollyea, et. al.Daniel A Pollyea ... Jonathan A Gutman
06 Dec 2014
Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML
Andreas T Björklund ... Karl-Johan Malmberg
Blood | VOL. 130
Andreas T Björklund, et. al.Andreas T Björklund ... Karl-Johan Malmberg
25 Jun 2021
FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)
Sita D Bhella ... Karen Yee
Blood | VOL. 124
Sita D Bhella, et. al.Sita D Bhella ... Karen Yee
06 Dec 2014
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
...
The Lancet Haematology | VOL. 7
, et. al. ...
05 Sep 2020
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Advances in RNA editing in hematopoiesis and associated malignancies.
Shuangshuang Pu ... Hui Cheng
Blood | VOL. -
Shuangshuang Pu, et. al.Shuangshuang Pu ... Hui Cheng
27 Jan 2025
Protection of β2GPI-Deficient Mice from Thrombosis Reflects a Defect in PAR3-facilitated Platelet Activation.
Paresh P Kulkarni ... Keith R Mccrae
Blood | VOL. -
Paresh P Kulkarni, et. al.Paresh P Kulkarni ... Keith R Mccrae
27 Jan 2025
Babesiosis and Sickle Red blood Cells: Loss of Deformability, Heightened Osmotic fragility, and Hypervesiculation.
Divya Beri ... Cheryl A Lobo
Blood | VOL. -
Divya Beri, et. al.Divya Beri ... Cheryl A Lobo
27 Jan 2025
Platelet activation and signaling in thrombus formation.
Frauke Swieringa ... Alice Assinger
Blood | VOL. -
Frauke Swieringa, et. al.Frauke Swieringa ... Alice Assinger
27 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.